View article

Secondary metabolites of marine invertebrates show exceptional promise as potential pharmaceuticals in many therapeutic areas.[1] The main obstacle to the exploitation of these chemically diverse and often complex bioactive marine metabolites is the economic issue of a sustainable supply. Different strategies have been attempted to overcome this impediment, as long-term harvesting of wild stocks from the environment is generally considered unsound.[2] Whole organism aquaculture, tissue culture, symbiont culture and chemical synthesis are possible, but seldom provide the robust and economic yield needed for a commercially viable global supply. One promising option is to clone the biosynthetic genes that encode the expression of a lead metabolite into a surrogate host suitable for industrial-scale fermentation. Accordingly, we demonstrate the recombinant expression for biosynthesis of a bioactive marine …